Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-302: pemigatinib versus gemcitabine + cisplatin as first-line therapy for unresectable or metastatic FGFR2-rearranged cholangiocarcinoma
MOH_2019-05-11_007114Phase 3Not yet recruiting
- Sponsor
- Incyte
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pemigatinib in cholangiocarcinoma (CCA) (2 arms), sponsored by Incyte. Primary endpoint: Progression-free survival. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
pemigatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on MOH_2019-05-11_007114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-11_007114.